Filling in the Treatment Gap for Patients With EGFR+ NSCLC
Xiuning Le, MD, PhD, discusses the limited treatment options available for patients with non–small cell lung cancer and an EGFR exon 20 mutation.
Xiuning Le, MD, PhD, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center in Houston, Texas discusses the limited treatment options available for patients with non–small cell lung cancer (NSCLC) and an EGFR exon 20 mutation.
There is currently no FDA approved agent to treat patients with EGFR or HER2 exon 20-positive NSCLC. Targeting these oncogenes is a great unmet medical need, explains Le, and although chemotherapy is still an option to treat patients with EGFR-positive NSCLC, it is important use all the tools that are available to treat this patient population.
Introducing a small molecule tyrosine kinase inhibitor such as poziotinib is important for the future treatment of EGFR and HER exon 20-positive NSCLC. The hope is to bring more options to field.
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer
August 20th 2024Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.
Read More
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
August 20th 2024Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.
Read More
